ADIHEX
18.8.2020 18:09:12 CEST | Business Wire | Press release
The Higher Organizing Committee of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) have announced that the 18th edition of the event will take place over seven days from September 27 to October 3, 2021, at the Abu Dhabi National Exhibition Centre (ADNEC), under the patronage of H.H. Sheikh Hamdan bin Zayed Al Nahyan, Ruler's Representative in Al Dhafra Region and Chairman of Emirates Falconers’ Club. The exhibition will extend for the first time in its history over 7 consecutive days, in line with its development strategy turning it into a comprehensive International fair.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200818005638/en/
H.E. Majed Ali Al Mansouri, Secretary-General of the Emirates Falconers’ Club and Chairman of the Higher Organizing Committee of ADIHEX, said that the kind gesture of the event’s patron, H.H. Sheikh Hamdan bin Zayed Al Nahyan, Ruler's Representative in Al Dhafra Region and Chairman of Emirates Falconers’ Club, and his directives to extend the exhibition for an entire week came as a result of the unprecedented eagerness from the event participants.
H.E. Al Mansouri explained that the extension will offer visitors and exhibitors a greater opportunity to benefit from the event to network and conclude their business deals. It will also help meet the rising aspirations of the visitors, including those interested in falconry, hunting and equestrian from around the world.
H.E. Majed Al Mansouri added that the event witnessed an impressive increase in visitor’s number reaching a total of 1.6 million from its launch to 2019 edition.
H.E. Al Mansouri reiterated that the next edition will be unique as it coincides with the UAE’s 50 years celebration of success and achievements, and the launch of the Golden Jubilee plan for the next 50 years.
The Emirates Falconers' Club has approved a strategic plan to maintain ADIHEX as the largest exhibition of its kind in the MEA region, over the coming years. The plan includes the expansion of the event’s space gradually; achieving a quantum leap in the number of local and international exhibitors and visitors.
H.E. AL Mansouri said: “while preparing for the next 50 years, The UAE has made unique achievements in various fields over the past decades; and has managed to occupy leading positions regionally and globally in the field of government efficiency and economic competitiveness while preserving its heritage at the same time.
The next edition of ADIHEX will be held under the theme ‘Sustainability and Heritage… A Reborn Aspiration’, which reflects the efforts of Abu Dhabi and the world to promote environmental and sustainable hunting, heritage sports and related industries.
ADIHEX provides its participants and visitors with a comprehensive offering within its 11 sectors: veterinary products and services, hunting guns, media, outdoor leisure vehicles and equipment, hunting tourism and safari, arts and crafts, equestrian, falconry, fishing and marine sports, hunting and camping equipment and cultural heritage.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005638/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom